Abstract:
The present invention is directed to cochleate composition that include a nucleotide. The nucleotide may generally be bound via a linker to a component of the cochleate, or to a lipophilic tail. Additionally or alternatively, the nucleotide may he associated with a transfection agent. The present invention also includes methods for making and using, the compositions provided herein.
Abstract:
Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.
Abstract:
Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
Abstract:
Disclosed are cochleates and cochleate compositions that associated with an replacement enzyme component and/or a plasmid component that encodes a replacement enzyme. Also disclosed are methods of making and using the compositions of the invention, including methods of administration. Use of the invention provides safe, effective and efficient delivery of replacement enzymes and/or plasmids encoding the same in a variety of dosage forms.
Abstract:
The present invention provides novel fragile nutrient cochleates that generally include one or more encochleated fragile nutrients, e.g., beta carotene, and methods for making the same. Also provided are methods for the use and administration of the fragile nutrient cochleates of the invention.
Abstract:
Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
Abstract:
An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.
Abstract:
Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.
Abstract:
The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for later addition of cargo moieties are also contemplated.
Abstract:
Disclosed herein are cochleates and cochleate compositions associated with an apoprotein component and/or a plasmid component that encodes an apoprotein. Also disclosed are methods of making and using the compositions of the invention, including methods of administration. Use of the invention provides safe, effective and efficient delivery of apoproteins and/or plasmids encoding the same in a variety of dosage forms.